Medical Marijuana and Women's Health: From Menstrual Pain to Menopause

Queen Victoria's personal physician, Sir J. Russell Reynolds, prescribed cannabis for her menstrual cramps in 1890. He wrote in The Lancet that cannabis was "one of the most valuable medicines we possess." Over a century later, millions of women are rediscovering what a Victorian-era doctor already documented — medical marijuana can be a powerful tool for conditions that disproportionately affect women.

Yet women remain underrepresented in cannabinoid research. Most clinical trials skew male, and dosing guidelines rarely account for differences in body composition, hormonal fluctuation, or endocannabinoid tone between sexes. That's starting to change, and the emerging data is worth paying attention to.

The Endocannabinoid System Has a Gender Component

Your endocannabinoid system (ECS) — the network of receptors, enzymes, and endogenous cannabinoids that regulate pain, mood, inflammation, and reproductive function — doesn't operate identically in men and women.

Estrogen modulates endocannabinoid signaling. Research published in Frontiers in Neuroscience (2020) found that estradiol increases anandamide levels and upregulates CB1 receptor expression in certain brain regions. This means your sensitivity to cannabinoids fluctuates across your menstrual cycle:

• Follicular phase (days 1-14): Rising estrogen may enhance cannabinoid sensitivity
• Luteal phase (days 15-28): Declining estrogen and rising progesterone may reduce it
• Perimenopause and menopause: Dropping estrogen correlates with decreased endocannabinoid tone

This has practical implications. Some women report needing less medical marijuana during the first half of their cycle and more during the second half. It also helps explain why women and men sometimes respond differently to the same dose.

Menstrual Pain: Beyond "Just Take Ibuprofen"

Dysmenorrhea — painful periods — affects an estimated 45-95% of menstruating women, depending on the study. Primary dysmenorrhea, caused by prostaglandin-driven uterine contractions, is the most common gynecological complaint worldwide. And yet the standard advice hasn't changed in decades: NSAIDs, heating pads, maybe hormonal birth control.

THC is an analgesic and a smooth muscle relaxant. CBD is anti-inflammatory and modulates prostaglandin synthesis. Together, they address the actual mechanisms behind menstrual cramping.

A 2023 survey published in BMC Women's Health found that among women who used medical cannabis for menstrual symptoms, 85% reported significant pain reduction. Notably, many respondents reported decreasing or eliminating NSAID use — relevant given the GI side effects of chronic NSAID use.

What the research suggests:

• THC activates CB1 receptors in the uterus, reducing contractile intensity
• CBD inhibits COX-2 enzyme activity, the same target as ibuprofen, but through a different pathway
• Beta-caryophyllene, a terpene found in many medical marijuana strains, selectively activates CB2 receptors and has demonstrated anti-inflammatory effects in preclinical models

At CORAL, Dr. Kim discusses these mechanisms with patients and helps identify products and routes of administration — topical, sublingual, or inhalation — that match the timing and severity of symptoms.

Endometriosis: A Condition the ECS Was Built For

Endometriosis affects roughly 1 in 10 women of reproductive age. Endometrial tissue grows outside the uterus — on the ovaries, fallopian tubes, bowel, and pelvic lining — causing chronic pain, inflammation, adhesions, and often infertility. Average time to diagnosis: 7-10 years.

The endocannabinoid system is heavily involved in endometriosis pathophysiology. A landmark study by Bouaziz et al. (2017) in Human Reproduction found significantly lower levels of endocannabinoid receptors in endometriotic tissue, suggesting clinical endocannabinoid deficiency in affected tissue.

Research from Sanchez et al. (2012) demonstrated that CB1 agonists inhibited endometriotic cell proliferation in vitro. A 2020 study in eLife by Dmitrieva et al. showed that activation of CB2 receptors reduced inflammatory lesion size in animal models of endometriosis.

Why medical marijuana may help endometriosis patients:

• Pain modulation: Endometriosis pain involves nociceptive, neuropathic, and central sensitization components — all of which are modulated by the ECS
• Inflammation: THC and CBD both have anti-inflammatory properties, working through different mechanisms
• GI symptoms: Many endometriosis patients have bowel involvement; cannabinoids can reduce gut inflammation and spasm
• Sleep disruption: Chronic pain disrupts sleep; THC in particular has demonstrated sleep-promoting effects
• Opioid reduction: A 2021 survey in the Journal of Minimally Invasive Gynecology found that 56% of endometriosis patients using medical cannabis reduced their opioid use

Current treatment for endometriosis — hormonal suppression, laparoscopic excision, GnRH agonists — addresses different aspects of the disease. Medical marijuana doesn't replace these interventions, but it can meaningfully improve quality of life alongside them.

Menopause: When the ECS Loses Its Anchor

Menopause is not a disease. But the symptoms it produces — hot flashes, insomnia, mood changes, vaginal dryness, joint pain, anxiety, cognitive fog — are real and can be debilitating. Hormone replacement therapy (HRT) is effective but not appropriate or desired by every woman.

Here's where the ECS connection gets interesting. Estrogen is a key regulator of endocannabinoid tone. When estrogen drops permanently at menopause, endocannabinoid signaling drops with it. Researchers including Dr. Ethan Russo have hypothesized that some menopausal symptoms may partly reflect endocannabinoid deficiency.

Symptom-by-symptom evidence:

• Hot flashes: The hypothalamus regulates thermoregulation and is rich in CB1 receptors. Anandamide modulates hypothalamic temperature set points. A 2022 observational study found that 67% of menopausal women using medical cannabis reported improvement in vasomotor symptoms.
• Insomnia: THC, particularly in low doses, reduces sleep latency. CBN, another minor cannabinoid, has sedative properties. A 2023 review in Sleep Medicine Reviews found that cannabis use was associated with improved subjective sleep quality in menopausal women.
• Mood and anxiety: CBD modulates serotonin receptors (5-HT1A) and has anxiolytic effects in clinical trials. This is particularly relevant during perimenopause when hormonal fluctuation amplifies anxiety.
• Joint pain: Menopausal arthralgia affects up to 50% of postmenopausal women, likely related to estrogen's anti-inflammatory effects disappearing. Cannabinoids address both inflammatory and pain pathways.
• Bone density: Preclinical research is preliminary but intriguing — CB2 receptor activation appears to stimulate osteoblast activity and bone formation. A 2009 study in Cell Metabolism showed that CB2-deficient mice developed accelerated osteoporosis.

What About Fertility and Pregnancy?

This requires a direct answer: medical marijuana should be avoided during pregnancy and while trying to conceive.

THC crosses the placental barrier. The American College of Obstetricians and Gynecologists (ACOG) recommends against cannabis use during pregnancy and lactation. Research has associated prenatal cannabis exposure with lower birth weight and potential neurodevelopmental effects, though disentangling cannabis effects from confounders (tobacco use, socioeconomic factors) remains methodologically challenging.

For women using medical marijuana who plan to become pregnant, the responsible approach is to taper off before conception. At CORAL, Dr. Kim has these conversations directly — there's no judgment, just honest guidance about timing and alternatives during the preconception and pregnancy period.

Dosing Considerations Specific to Women

Pharmacokinetic research suggests women may need to approach medical marijuana dosing differently:

1. Body fat distribution: THC is lipophilic (fat-soluble). Women generally have higher body fat percentages, which can affect how THC is stored, metabolized, and released. This can lead to longer-lasting effects and a different tolerance trajectory.

1. Hormonal interactions: As discussed, estrogen modulates ECS sensitivity. Tracking symptoms relative to your cycle can help optimize timing and dosing.

1. Metabolism: Women tend to have lower levels of CYP3A4, a liver enzyme involved in THC metabolism. This can result in higher effective blood levels from the same dose.

1. Biphasic response: Low-dose THC tends to be anxiolytic; high-dose THC can be anxiogenic. Women who are more cannabinoid-sensitive during high-estrogen phases may find their therapeutic window shifts accordingly.

Practical recommendations:

• Start lower than standard recommendations suggest (2.5 mg THC or less for edibles)
• Track response across your menstrual cycle if applicable
• Consider higher CBD ratios if anxiety is a concern
• Discuss any hormonal medications (HRT, birth control) with your certifying physician — not because of dangerous interactions, but because coordinating the effects matters

The Historical Context Matters

The use of medical cannabis by women isn't a modern phenomenon. It's an ancient one interrupted by 20th-century prohibition.

• Ancient Egypt (1550 BCE): The Ebers Papyrus describes cannabis preparations for gynecological conditions
• Medieval Europe: Cannabis was used in midwifery and for postpartum pain
• 19th-century America: Cannabis tinctures were widely prescribed for menstrual pain, available in pharmacies without prescription
• 1937: The Marihuana Tax Act effectively ended legal medical use, removing a tool from the gynecological toolkit

The modern medical marijuana movement is restoring access to something women used safely for millennia — now with the benefit of pharmacological understanding, standardized products, and physician oversight.

Moving Forward

Women's health conditions remain chronically underresearched and undertreated. Endometriosis takes a decade to diagnose. Menstrual pain is dismissed as normal. Menopausal symptoms are treated as an inevitability. Medical marijuana won't fix the systemic problems in how women's health is approached, but it is a legitimate therapeutic option for symptoms that affect daily life.

If you're a Florida resident dealing with menstrual pain, endometriosis, menopausal symptoms, or other qualifying conditions, medical marijuana certification is straightforward. At CORAL, Dr. Kim provides evaluations via telehealth — no waiting rooms, no judgment, just an honest conversation about whether medical marijuana makes sense for your situation.

Ready to explore whether medical marijuana could help? [Start your evaluation at coral.clinic/start](https://coral.clinic/start).